Explore 3 Stock Ideas & Industry Insights Download Free Report

PharmaCyte Biotech Inc

Company price
5.42 USD 0.00(0%)
Last update at 2026-11-18T19:49:00Z
VOLUME
6113
Market Cap
4.10M

Momentum Score

…

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.35
Low
5.51
High
52 Week Price Range
0.33
Low
1.51
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

PharmaCyte Biotech is a clinical-stage company developing a cell-encapsulation platform (Cell-in-a-Box) to localize therapeutic activity, principally applied to pancreatic cancer with earlier-stage work in metabolic disease. Long-term growth may be driven by positive clinical trial results, regulatory progress, and partnerships or licensing that expand use of the platform. Investors may find the company attractive for its differentiated local prodrug activation approach that could improve tumor targeting and limit systemic toxicity if trials are successful.
The principal investment risks are high clinical and regulatory uncertainty for a single-platform, capital-intensive small company that currently lacks commercial revenues and may require additional financing, exposing shareholders to dilution and execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.42
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-43.99%
Net Debt
-18.60M
ROCE
-14.92%
Diluted EPS TTM
-2.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Income before tax -19.42M 30.66M 0.33M -4.32M -4.24M
Net income -19.42M 30.66M 0.33M -4.32M -4.09M
Selling general administrative 4.91M 3.94M 6.11M 5.99M 3.70M
Selling and marketing expenses - - 1.32M - -
Ebit - 26.28M 0.33M -6.46M -4.39M
Ebitda -5.30M -4.38M -6.52M -4.32M -4.24M
Depreciation and amortization - 4.38M 6.52M 2.14M 0.15M
Operating income -6.85M -4.38M -8.52M -6.46M -4.39M
Other operating expenses 6.85M 4.38M 8.52M 6.46M 4.39M
Interest expense - - - 0.00M 0.00M
Tax provision 0.00M 0.00M - - -
Interest income 0.73M 1.42M 3.40M 1.94M 0.16M
Net interest income 0.73M 1.42M 3.40M 1.94M 0.16M
Income tax expense - - -6.52M -1.94M -0.15M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 6.85M 4.38M 8.52M 6.46M 4.39M
Total other income expense net -12.57M 35.03M 8.85M 0.20M 0.15M
Net income from continuing ops -19.42M 30.66M 0.33M -4.32M -4.24M
Net income applicable to common shares - - - - -4.24M
Breakdown 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total assets 46.75M 55.17M 59.90M 73.28M 90.62M
Intangible assets - 1.55M 1.55M 3.55M 3.55M
Other current assets 0.10M 3.14M 0.26M 0.11M 0.09M
Total liab 11.77M 3.28M 20.39M 0.59M 0.70M
Total stockholder equity 33.29M 51.89M 39.51M 72.69M 89.92M
Other current liab 0.56M 2.52M 6.69M 0.46M 0.50M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 1.27M 0.00M 11.87M 0.00M 0.00M
Retained earnings -104.39M -84.97M -115.63M -115.96M -111.65M
Other assets - - - - 0.01M
Cash 18.60M 15.17M 50.18M 68.04M 85.40M
Total current liabilities 0.83M 2.91M 7.42M 0.59M 0.70M
Net debt -18.60M -15.17M -50.18M -68.04M -85.40M
Other stockholder equity 137.71M 136.88M 143.29M 188.67M 201.58M
Total current assets 37.42M 22.38M 50.44M 68.15M 85.49M
Long term investments 0.00M 22.47M 0.00M 1.57M 1.57M
Net tangible assets - - - - 86.37M
Short term investments 18.48M 0.37M 0.00M - -
Net receivables 0.24M 3.70M - - -
Accounts payable 0.27M 0.40M 0.39M 0.13M 0.21M
Accumulated other comprehensive income -0.02M -0.02M -0.02M -0.02M -0.02M
Non currrent assets other 9.33M 8.77M 7.91M 0.01M 0.01M
Non current assets total 9.33M 32.79M 9.46M 5.13M 5.13M
Breakdown 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2026-04-30 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Investments -3.00M -7.00M -5.00M 0.00M 0.00M
Change to liabilities - - - - 0.03M
Total cashflows from investing activities 2.00M -7.00M -5.00M - -
Net borrowings - - - - -0.05M
Total cash from financing activities 6.58M -25.03M -10.71M -13.56M 87.31M
Change to operating activities - - - - -0.02M
Net income -19.42M 30.66M 0.33M -4.32M -4.24M
Change in cash 3.43M -35.01M -17.86M -17.36M 83.20M
Begin period cash flow 15.17M 50.18M 68.04M 85.40M 2.20M
End period cash flow 18.60M 15.17M 50.18M 68.04M 85.40M
Total cash from operating activities -5.15M -2.98M -2.15M -3.79M -4.12M
Issuance of capital stock 6.18M 0.00M 33.65M 0.00M 87.36M
Other cashflows from investing activities 2000000.00M - -5.00M - -
Dividends paid 0.25M 1.13M 22.46M - -
Sale purchase of stock -0.40M -25.03M -44.36M -13.56M -
Other cashflows from financing activities 6.18M -21.36M 17.49M 0.00M 87.31M
Change to netincome - - - - 0.11M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -1.92M 1.36M 0.30M -0.30M 0.01M
Stock based compensation 1.13M 0.48M 0.67M 0.65M 0.08M
Other non cash items 15.07M -35.47M -3.46M 0.17M 0.03M
Free cash flow -5.15M -2.98M -2.15M -3.79M -4.12M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PMCB
PharmaCyte Biotech Inc
-
-%
5.42 - 7.02 12904.41 0.12 14270.44 -12.02
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

PharmaCyte Biotech Inc

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169

917 595 2850

2

Name Title Year Born
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 1958
Mr. Joshua N. Silverman Interim CEO, Interim Pres & Interim Chairman 1970
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer 1957
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant NA
Mr. Joshua N. Silverman Interim CEO, President & Director 1970
Mr. Joshua N. Silverman CEO. President & Executive Chairman 1970
Mr. Carlos A. Trujillo CPA Chief Financial Officer 1958
Dr. Hans-Peter Hammes M.D. Member of Medical & Scientific Advisory Board and Consultant NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…